VGI Health Technology (XNEC:VTL) EV-to-EBIT : (As of May. 30, 2024)

View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, VGI Health Technology's Enterprise Value is A$0.00 Mil. VGI Health Technology does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate VGI Health Technology's EV-to-EBIT at this moment.

The historical rank and industry rank for VGI Health Technology's EV-to-EBIT or its related term are showing as below:

XNEC:VTL's EV-to-EBIT is not ranked ^*
in the Biotechnology industry.
Industry Median: 9.74
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. VGI Health Technology's Enterprise Value for the quarter that ended in . 20 was A$0.00 Mil. VGI Health Technology does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate VGI Health Technology's Earnings Yield (Joel Greenblatt) % at this moment.

VGI Health Technology EV-to-EBIT Historical Data

The historical data trend for VGI Health Technology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VGI Health Technology EV-to-EBIT Chart

VGI Health Technology Annual Data

Trend

EV-to-EBIT

VGI Health Technology Semi-Annual Data

EV-to-EBIT

Competitive Comparison of VGI Health Technology's EV-to-EBIT

For the Biotechnology subindustry, VGI Health Technology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VGI Health Technology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's EV-to-EBIT falls into.

VGI Health Technology EV-to-EBIT Calculation

VGI Health Technology's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/
	=

VGI Health Technology (XNEC:VTL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

VGI Health Technology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: . 20 )	=	EBIT	/	Enterprise Value (Q: . 20 )
	=		/
	=	%

VGI Health Technology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

VGI Health Technology (XNEC:VTL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003

Website

https://www.vgiht.com

VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines